The treatment is a once-daily steroid-free foam and is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
Seborrheic dermatitis is a common yet chronic form of eczema that causes red, itchy skin on the upper back, nose or scalp. It currently affects more than 10 million people in the United States
“Despite being a very common condition with significant negative impact on quality of life, seborrheic dermatitis has largely been overlooked by the pharmaceutical industry,” said Todd Edwards, chief commercial officer at Arcutis.
“We are proud to launch our second commercial product in the United States and have it immediately available in pharmacies with strong reimbursement from the major pharmacy benefit managers through our already established contracts.”
According to Arcutis, the foam provides rapid disease clearance and significant reduction in itch. It will be available via wholesaler and pharmacy channels across the U.S. this week.
In clinical trials, ZORYVE provided complete clearance of the condition for more than half of all subjects, and 3 in 4 patients achieved IGA treatment success at 8 weeks, with greater than 40% achieving IGA treatment success as early as two weeks.
Based on these attributes, Raj Chovatiya, dermatologist and clinical investigator, said the treatment has the potential to define a new standard of care for seborrheic dermatitis.
“Following decades without significant innovation in seborrheic dermatitis treatment, it’s exciting to have an approved, targeted treatment option for such a common yet burdensome inflammatory disease," he added.
“ZORYVE foam possesses several unique qualities that address unmet needs of seborrheic dermatitis patients. Notably, ZORYVE foam offers once-daily application, a water-based foam vehicle that can be used anywhere on the body, and versatility for use across all skin and hair types as well as the full spectrum of disease severity."
